Preview

Russian Journal of Gastroenterology, Hepatology, Coloproctology

Advanced search

Extraintestinal manifestations of inflammatory bowel diseases: arthropathy and arthritis

https://doi.org/10.22416/1382-4376-2016-6-101-105

Abstract

Aim of review. To present major extraintestinal manifestations of inflammatory bowel diseases (IBD) and basic approaches to management of patients with ulcerative colitis and Crohn's disease having arthropathies and arthrites as extraintestinal manifestations. Summary. Ulcerative colitis and Crohn's disease represent the group of the diseases with unknown etiology encompassed by the term «inflammatory bowel diseases». IBDs are diseases with high social impact due to predominance of young patients of working-age and tendency to chronization of pathological process that leads to deterioration of life of patients and high demand in hospital stay. Ulcerative colitis and Crohn's disease have diverse clinical presentation with various intestinal complications and extraintestinal manifestations. The results of original studies corresponding to world literary data and data of the First European evidencebased consensus on extra-intestinal manifestations in inflammatory bowel disease are presented in this article. Presented data indicates severity and aggressive course of the IBD-associated arthropathies, their contribution to quality of life deterioration and risk of disability that requires diagnostics, timely and adequate pharmacological treatment with multidisciplinary approach. Resolution of this issue is not only an actual trend, but a demand of worldwide medical community for treatment and rehabilitation IBD patients as well. Conclusion. Meditate analysis of extraintestinal IBD manifestations, in particular IBD-associated arthropathy and arthritis, expands potential of time the diagnosis and adequate drug treatment to decrease disability risk and to improve quality of life of IBD patients.

About the Author

Gulustan Hamid Sadygova
Azerbaijan State Advanced Training Institute for Doctors named after A.Aliyev
Russian Federation


References

1. Bernstein C. N., Blanchard J. F., Rawsthorne P., et al. The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. Am J Gastroenterol 2001; 96:1116-22.

2. Bourikas L. A., Papadakis K. A. Musculoskeletal manifestations of inflammatory bowel disease. Inflam Bowel Dis 2009; 15:1915-24.

3. El Miedany Y., Youssef S., Ahmed I., et al. The gastrointestinal safety and effect on disease activity of etoricoxib, a selective cox-2 inhibitor in inflammatory bowel diseases. Am J Gastroenterol 2006; 101:311-7.

4. Ferraz M. B., Tugwell P., Goldsmith C. H., et al. Metaanalysis of sulfasalazine in ankylosing spondylitis. J Rheumatol 1990; 17:1482-6.

5. Fornaciari G., Salvarani C., Beltrami M., et al. Muscoloskeletal manifestations in inflammatory bowel disease. Canadian J Gastroenterol 2001; 15:399-403.

6. Generini S., Giacomelli R., Fedi R., et al. Infliximab in spondyloarthropathy associated with Crohn’s disease: an open study on the efficacy of inducing and maintaining remission of musculoskeletal and gut manifestations. Ann Rheum Dis 2004; 63:1664-9.

7. Herfarth H., Obermeier F., Andus T., et al. Improvement of arthritis and arthralgia after treatment with infliximab (Remicade) in a German prospective, openlabel, multicenter trial in refractory Crohn’s disease. Am J Gastroenterol 2002; 97:2688-90.

8. Hindorf U., Johansson M., Eriksson A., et al. Mercaptopurine treatment should be considered in azathioprine intolerant patients with inflammatory bowel disease. Aliment Pharmacol Ther 2009; 29:654-61.

9. Leclerc-Jacob S., Lux G., Rat A. C., et al. The prevalence of inflammatory sacroiliitis assessed on magnetic resonance imaging of inflammatory bowel disease: a retrospective study performed on 186 patients. Aliment Pharmacol Ther 2014; 39:957-62.

10. Marzo-Ortega H., McGonagle D., O’Connor P., et al.Efficacy of etanercept for treatment of Crohn’s related spondyloarthritis but not colitis. Ann Rheum Dis 2003; 62:74-6.

11. Mendoza J. L., Lana R., Taxonera C., et al. Extraintestinal manifestations in inflammatory bowel disease: differences between Crohn’s disease and ulcerative colitis. Med Clin (Barc) 2005; 125:297-300.

12. Orchard T. R., Holt H., Bradbury L., et al. The prevalence, clinical features and association of HLA-B27 in sacroiliitis associated with established Crohn’s disease. Aliment Pharmacol Ther 2009; 29:193-7.

13. Palm O., Moum B., Ongre A., et al. Prevalence of ankylosing spondylitis and other spondyloarthropathies among patients with inflammatory bowel disease: a population study (the IBSEN study). J Rheumatol 2002; 29:511-5.

14. Poddubnyy D., Rudwaleit M., Haibel H., et al. Rates and predictors of radiographic sacroiliitis progression over 2 years in patients with axial spondyloarthritis. Ann Rheum Dis 2011; 70:1369-74.

15. Rodríguez-Reyna T.S., Martínez-Reyes C., YamamotoFurusho J. K. Rheumatic manifestations of inflammatory bowel disease. World J Gastroenterol 2009; 15:5517-24.

16. Salvarani C., Fries W. Clinical features and epidemiology of spondyloarthritides associated with inflammatory bowel disease. World J Gastroenterol 2009; 15:2449-55.

17. Salvarani C., Vlachonikolis I. G., van der Heijde D. M., et al. Musculoskeletal manifestations in a populationbased cohort of inflammatory bowel disease patients. Scand J Gastroenterol 2001; 36:1307-13.

18. Sandborn W. J., Stenson W. F., Brynskov J., et al. Safety of celecoxib in patients with ulcerative colitis in remission: a randomized, placebo-controlled, pilot study. Clin Gastroenterol Hepatol 2006; 4:203-11.

19. Steer S., Jones H., Hibbert J., et al. Low back pain, sacroiliitis, and the relationship with HLA-B27 in Crohn’s disease. J Rheumatol 2003; 30:518-22.

20. The first european evidence-based consensus on extraintestinal manifestations in inflammatory bowel disease. J Crohn’s and Colitis 2016; 10(3):239-25.

21. Van den Bosch F., Kruithof E., de Vos M., et al.

22. Crohn’s disease associated with spondyloarthropathy: effect of TNF-alpha blockade with infliximab on articular symptoms. Lancet 2000; 356:1821-2.

23. Vavricka S. R., Brun L., Ballabeni P., et al. Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort. Am J Gastroenterol 2011; 106:110-9.

24. Vavricka S. R., Rogler G., Gantenbein C., et al. Chronological order of appearance of extraintestinal manifestations relative to the time of IBD diagnosis in the Swiss inflammatory bowel disease cohort. Inflamm Bowel Dis 2015.

25. Veloso F. T., Carvalho J., Magro F. Immune-related systemic manifestations of inflammatory bowel disease. A prospective study of 792 patients. J Clin Gastroenterol 1996; 23:29-34.

26. Vind I., Riis L., Jess T., et al. Increasing incidences of inflammatory bowel disease and decreasing surgery rates in Copenhagen City and County, 2003-2005: a populationbased study from the Danish Crohn colitis database. Am J Gastroenterol 2006; 101:1274-82.

27. Yüksel I., Ataseven H., Başar O., et al. Peripheral arthritis in the course of inflammatory bowel diseases. Dig Dis Sci 2011; 56:183-7.

28. Zochling J., van der Heijde D., Dougados M., et al. Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS/ EULAR management recommendations in ankylosing spondylitis. Ann Rheum Dis 2006; 65:423-32.


Review

For citations:


Sadygova G.H. Extraintestinal manifestations of inflammatory bowel diseases: arthropathy and arthritis. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2016;26(6):101-105. (In Russ.) https://doi.org/10.22416/1382-4376-2016-6-101-105

Views: 3448


ISSN 1382-4376 (Print)
ISSN 2658-6673 (Online)